



6TH ANNUAL MSK SYMPOSIUM ON
LYMPHOMA

MAY 13-14, 2022 • VIRTUAL

*Featuring Updated Information on
Current and Future Therapies
for Lymphoma*

mskcc.org/LymphomaSymposium



Memorial Sloan Kettering
Cancer Center



Welcome

On behalf of the course planning committee and faculty, we invite you to attend the **6th Annual MSK Symposium on Lymphoma**.

This symposium will feature updated information on lymphoma biology, diagnosis, and ongoing efforts to translate the scientific discoveries into novel treatment strategies for a variety of lymphoma subtypes. **This year, we will address the clinical management of the most frequent lymphoma entities and will feature focused sessions related to new families of drugs being developed in these areas as well as in less common presentations.** Faculty will present those and then discuss, during a panel, how to best approach patients' situations. We will also cover, in a special session, recent advances in the biology of lymphoma and how this will translate to innovative therapeutic interventions.

Participants will have the opportunity to discuss diagnostic and management cases, and how to incorporate biomarkers and imaging into clinical practice and clinical trials.

By attending this program, attendees will be able to:

- Describe recent refinements in lymphoma classification
- Discuss first line treatment options in most frequent lymphoma entities
- Identify risks/benefits of new approved agents
- Implement standard of care changes for patients with lymphoma
- Educate patients on the disease and treatment options


The target audience for this symposium includes internists, oncologists, hematologists as well as medical and radiation oncologists, hematopathologists, scientists, and medical trainees involved in diagnosis, treatment, and biomedical research of lymphoma.

We look forward to seeing you virtually in May.



MSK Course Director

Gilles Salles, MD, PhD
Chief, Lymphoma Service



MSK Course Planning Committee



Ahmet Dogan, MD, PhD
Chief, Hematopathology Service



David Qualls, MD
Medical Oncology/Hematology Fellow



Steven Horwitz, MD
Attending
Lymphoma Service



Hans-Guido Wendel, MD
Member/Professor
Cancer Biology and Genetics Program




Andrew Intlekofer, MD
Assistant Attending
Lymphoma Service



Joachim Yahalom, MD
Attending
External Beam Radiotherapy Service



Ariela Noy, MD
Attending
Lymphoma Service



Andrew D. Zelenetz, MD, PhD
Medical Director, Quality Informatics

Invited Course Faculty

Ranjana Advani, MD

Saul Rosenberg Professor of Lymphoma
Stanford University
Stanford, CA

Eric Hsi, MD

Professor and Chair
Department of Pathology
Wake Forest School of Medicine
Winston-Salem, NC

Tyrel Phillips, MD

Clinical Associate Professor
Professor of Medicine
University of Michigan
Ann Arbor, MI

Stephen Ansell, MD, PhD

Dorothea W. and Grant L. Sundquist Professor
in Hematologic Malignancies Research
Chair, Lymphoma Group
Mayo Clinic
Rochester, MN

Peter Johnson, MD

Professor of Medical Oncology
University of Southampton
United Kingdom

Vincent Rajkumar, MD

Edward W. and Betty Knight Scripps
Professor of Medicine
Mayo Clinic
Rochester, MN

Renier Brentjens, MD, PhD

Deputy Director
Chair, Department of Medicine
Professor of Oncology,
Departments of Medicine & Immunology
Katherine Anne Gioia Endowed Chair
of Medicine
Roswell Park Comprehensive Cancer Center
Buffalo, NY

Brad Kahl, MD

Professor
Washington University School of Medicine
St. Louis, MO

Mark Roschewski, MD

Senior Clinician
National Cancer Institute
Bethesda, MD

Jaehyuk Choi, MD

Associate Professor
Feinberg School of Medicine
Chicago, IL

Ann LaCasce, MD, MMSc

Associate Professor of Medicine,
Program Director
Dana-Farber/Mass General Brigham
Fellowship in Hematology Oncology
Boston, MA

Karin Tarte, PhD, PharmD

Director, Professor
Rennes Medical School
France

Ming-Qing Du, MB, PhD

Professor
University of Cambridge
United Kingdom

Franck Morschhauser, MD, PhD

Professor of Hematology
Universite de Lille, CHU Lille
France

Jason Westin, MD, MS

Director, Lymphoma Clinical Research
Section Chief, Aggressive Lymphoma
The University of Texas
MD Anderson Cancer Center
Houston, TX

Thomas Habermann, MD

Hematologist
Mayo Clinic
Rochester, MN

Sattva Neelapu, MD

Professor
The University of Texas
MD Anderson Cancer Center
Houston, TX

Roberta Zappasodi, PhD

Assistant Professor of Hematology
in Medicine
Weill Cornell Medicine
New York, NY

MSK Course Faculty

Connie Lee Batlevi, MD, PhD

Assistant Attending
Lymphoma Service

Philip C. Caron, MD, PhD

Attending
Lymphoma Service

Ahmet Dogan, MD, PhD

Chief, Hematopathology Service

Zachary Epstein-Peterson, MD

Assistant Attending
Lymphoma Service

Lorenzo Falchi, MD

Assistant Attending
Lymphoma Service

Audrey M. Hamilton, MD

Laboratory Director, MSK Basking Ridge
Attending
Lymphoma Service

Paul A. Hamlin, MD

Medical Director, David H. Koch Center
for Cancer Care
Associate Attending
Lymphoma Service

Steven Horwitz, MD

Attending
Lymphoma Service

Brandon Imber, MD, MA

Assistant Attending
External Beam Radiotherapy Service

Andrew Intlekofer, MD

Assistant Member
Human Oncology & Pathogenesis Program

William Johnson, DO

Assistant Attending
Lymphoma Service

Niloufer Khan, MD, MS

Assistant Attending
Lymphoma Service

Anita Kumar, MD

Assistant Attending
Lymphoma Service

Jennifer K. Lue, MD

Assistant Attending
Lymphoma Service

Anthony Mato, MD, MSCE

Director, CLL Program
Associate Attending
Leukemia Service

Matthew J. Matasar, MD

Associate Attending
Hematology/Lymphoma Services

Marius E. Mayerhoefer, MD, PhD

Attending
Body Imaging/Molecular Imaging and
Therapy Services

Alison Moskowitz, MD

Clinical Director, Lymphoma
Associate Attending
Lymphoma Service

Ariela Noy, MD

Attending
Lymphoma Service

Colette N. Owens, MD

Assistant Attending
Lymphoma/Genitourinary Oncology Services

M. Lia Palomba, MD

Attending
Lymphoma Service

David Qualls, MD

Medical Oncology/Hematology Fellow

Gilles Salles, MD, PhD

Chief, Lymphoma Service

Leonard Saltz, MD

Executive Director, Clinical Value and Sustainability
Head, Colorectal Oncology Section
Attending
Gastrointestinal Oncology Service

David J. Straus, MD

Attending
Lymphoma Service

Robert Stuver, MD

Medical Oncology/Hematology Fellow

Beatriz Wills Sanin, MD

Chief Fellow, Hematology

Santosha Vardhana, MD


Assistant Attending
Lymphoma Service

Andrew D. Zelenetz, MD, PhD

Medical Director, Quality Informatics

FACULTY DISCLOSURE

It is the policy of MSK to make every effort to insure balance, independence, objectivity, and scientific rigor in all continuing medical education activities which it provides as an ACCME accredited provider. In accordance with ACCME guidelines and standards, all faculty participating in an activity provided by MSK are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services which are discussed by the faculty members in an educational presentation. As required by the ACCME, when an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, MSK requires the speaker to disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Friday, May 13, 2022	
7:45-7:55 AM	Virtual Course Check-in
7:55-8:00 AM	Welcome and Introduction Gilles Salles, MD, PhD
Plenary Lecture MODERATOR: Gilles Salles, MD, PhD	
8:00-9:00 AM	 Circulating Tumor DNA in Lymphoma: Principles Learned and Future Directions Mark Roschewski, MD
Targeting the Microenvironment in Lymphoma MODERATOR: Andrew Intlekofer, MD	
9:00-9:20 AM	Follicular Lymphoma Microenvironment: What About Stromal Cell Origin and Function? Karin Tarte, PhD, PharmD
9:20-9:40 AM	The Role of PD1 in Cutaneous T Cell Lymphomas Jaehyuk Choi, MD
9:40-10:00 AM	Understanding Immunotherapy Resistance of B-cell Non-Hodgkin Lymphomas Roberta Zappasodi, PhD
10:00-10:20 AM	Strategies to Overcome Immunological Barriers in the Microenvironment in Lymphoma Stephen Ansell, MD, PhD
10:20-10:30 AM	Q&A/Panel Discussion
Update on Imaging and Theranostics MODERATOR: Andrew Intlekofer, MD	
10:30-11:00 AM	Novel Targets for Imaging of Lymphoma and Microenvironment Marius E. Mayerhoefer, MD, PhD
11:00-11:15 AM	Break
First Line Diffuse Large B-Cell Lymphoma: How to Improve the Chance of Cure? MODERATOR: Colette N. Owens, MD	
11:15-11:35 AM	Building on R-CHOP to Improve DLBCL Outcomes Franck Morschhauser, MD, PhD
11:35-11:55 AM	Chipping Away at CHOP: Can First Line Therapy Really be Chemotherapy Free? Jason Westin, MD, MS
11:55-12:05 PM	Q&A/Panel Discussion
High Grade B-cell Lymphoma Pathology: What Is New? MODERATOR: Colette N. Owens, MD	
12:05-12:25 PM	Recent Concepts in DLBCL/High Grade B-cell Lymphomas Eric Hsi, MD
12:25-12:55 PM	Lunch Break
Recent Optimization in the Management of Patients With Follicular Lymphoma MODERATOR: Audrey M. Hamilton, MD	
12:55-1:15 PM	Personalizing First Line Therapy in Patients with Follicular Lymphoma Gilles Salles, MD, PhD
1:15-1:35 PM	Options for Managing R/R Follicular Lymphoma Brad Kahl, MD
1:35-1:45 PM	Q&A/Panel Discussion
Mantle Cell Lymphoma: A Rapidly Evolving Landscape MODERATOR: Audrey M. Hamilton, MD	
1:45-2:00 PM	New Directions for the Frontline treatment of MCL Anita Kumar, MD
2:00-2:15 PM	Unmasking the Boogie Man: Novel Treatment Outpatients in R/R Mantle Cell Lymphoma Tycel Phillips, MD
2:15-2:25 PM	Q&A/Panel Discussion



Join the conversation with us:
#MSKlymphomaCME • #MSKCME

New Drugs Flash	
MODERATOR: Zachary Epstein-Peterson, MD	
2:25-2:45 PM	New Therapeutic Approaches in T-cell Lymphoma Steven Horwitz, MD Robert Stuver, MD
2:45-2:50 PM	Q&A/Panel Discussion
New Drugs Flash	
MODERATOR: Zachary Epstein-Peterson, MD	
2:50-3:05 PM	Improving BTK and PI3K Inhibitors Andrew D. Zelenetz, MD, PhD
3:05-3:20 PM	Break
What is New in CLL Management?	
MODERATOR: Philip C. Caron, MD, PhD	
3:20-3:50 PM	CLL: State-of-the-Art Management and Recent Innovations Anthony Mato, MD, MSCE
Hot Topic	
MODERATOR: Paul A. Hamlin, MD	
3:50-4:15 PM	The High Cost of Cancer Drugs and What We Need to Do About It Vincent Rajkumar, MD
4:15-4:30 PM	Roundtable Discussion Steven Horwitz, MD Gilles Salles, MD, PhD Vincent Rajkumar, MD Leonard Saltz, MD
Flash Session	
MODERATOR: Jennifer K. Lue, MD	
4:30-4:45 PM	Managing Waldenström Macroglobulinemia in 2022 M. Lia Palomba, MD
New Drugs Flash	
MODERATOR: Jennifer K. Lue, MD	
4:45-5:00 PM	CTCL: Current Management and Future Directions Niloufer Khan, MD, MS
New Drugs Flash	
MODERATOR: Jennifer K. Lue, MD	
5:00-5:20 PM	Bispecific Antibodies in B-cell Lymphoma: A New Breakthrough? Lorenzo Falchi, MD David Qualls, MD
5:20-5:25 PM	Q&A/Panel Discussion
5:25-5:30 PM	Closing Remarks Gilles Salles, MD, PhD
5:30 PM	Adjourn

Attendees will have an opportunity to submit questions to the faculty throughout the program. Faculty will be available at the end of each session or presentation to answer questions.

Saturday, May 14, 2022

8:00-8:10 AM Virtual Course Check-in

8:10-8:15 AM **Welcome and Introduction**
Gilles Salles, MD, PhD

New Frontiers for Radiotherapy in Lymphoma

MODERATOR: Gilles Salles, MD, PhD

8:15-8:45 AM **New Frontiers for Radiotherapy in Lymphoma: Doing More with Less and Doing More with More**
Brandon Imber, MD, MA

Marginal Zone Lymphoma: Challenges in Diagnosis and Management

MODERATOR: Ahmet Dogan, MD, PhD

8:45-9:00 AM **Recent Advances in the Biology of MALT Lymphoma**
Ming-Qing Du, MB, PhD

9:00-9:15 AM **Options for First Line Management of Marginal Zone Lymphoma**
Thomas Habermann, MD

9:15-9:30 AM **Considerations for Relapsed and Refractory Marginal Zone Lymphoma**
Ariela Noy, MD

9:30-9:40 AM **Q&A/Panel Discussion**

Recent Advances in First Line Hodgkin Lymphoma Treatment

MODERATOR: David J. Straus, MD

9:40-9:55 AM **Optimizing Therapy in Early Stage Classic Hodgkin Lymphoma**
Ann LaCasce, MD, MMSc

9:55-10:10 AM **Advanced Stage Hodgkin Lymphoma: What Now?**
Peter Johnson, MD

10:10-10:20 AM **Q&A/Panel Discussion**

Flash Session

MODERATOR: David J. Straus, MD

10:20-10:40 AM **Updates in Management of Relapsed and Refractory Hodgkin Lymphoma**
Alison Moskowitz, MD
Beatriz Wills Sanin, MD

10:40-10:45 AM **Q&A/Panel Discussion**

10:45-11:00 AM Break

Hot Topic

MODERATOR: Matthew J. Matasar, MD

11:00-11:30 AM **CNS Prophylaxis in DLBCL: Navigating New Data**
Ranjana Advani, MD

Early Relapse in DLBCL: CAR T cells for All?

MODERATOR: Connie Lee Batlevi, MD, PhD

11:30-11:45 AM **CAR T Cell Therapy for Transplant Eligible and Ineligible**
Sattva Neelapu, MD

11:45-12:00 PM **Early Relapse DLBCL: CAR T Cell for Selected Patients**
Andrew D. Zelenetz, MD, PhD

12:00-12:10 PM **Q&A/Panel Discussion**

New Drugs Flash

MODERATOR: Connie Lee Batlevi, MD, PhD

12:10-12:25 PM **Driving CAR T cells Forward**
Renier Brentjens, MD, PhD

Plenary Lecture

MODERATOR: William Johnson, DO

12:25-1:15 PM



Adaptive Immune Dysregulation in Cancer Patients During SARS-CoV-2 Infection and Vaccination
Santosha Vardhana, MD

1:15-1:20 PM **Closing Remarks**
Gilles Salles, MD, PhD

1:20 PM Adjourn

Registration

Physicians (MDs, PhDs and DOs): \$200

Nurses, PAs and Other Healthcare Professionals: \$50

Residents and Fellows: \$50

Industry Professionals*: \$350

Register online at: mskcc.org/LymphomaSymposium

*Industry professionals may attend MSK CME activities for their own education. Marketing, sales, and promotion of products and services is strictly prohibited at MSK CME activities. For more information, please visit our website, mskcc.org/LymphomaSymposium.

Live Virtual Format

This live virtual program will be delivered using Zoom. We encourage all attendees to download the Zoom app prior to the start of the course (zoom.us/download). CME credit and ABIM MOC points will be offered for this live virtual program. Detailed access and credit instructions will be emailed to attendees prior to the start of the course.

Registration Discounts/Promotions

- A registration discount is available for MSK Alumni, and MSK Cancer Alliance to attend a MSK CME course. If you are a member of one of these groups, contact cme@mskcc.org for details.
- Registration is complimentary for all MSK employees; however, you must complete registration in order to attend this course.
- Please note that after your payment has been processed, no further promotional discounts or adjustments will be made to your registration.

Accreditation

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement


Memorial Sloan Kettering Cancer Center designates this live activity for a maximum of **13.25 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity

ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to **13.25 Medical Knowledge MOC points** in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.



Memorial Sloan Kettering
Cancer Center





Memorial Sloan Kettering
Cancer Center

mskcc.org/LymphomaSymposium